• Like
  • 1
  • Favorite

Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance

Stock Track10-03

Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.

On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.

However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment1

  • Kaboom
    ·10-03
    Sigh. This company is a joke 
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial